Mumbai-based Sun Pharma has settled its litigation with Allergan and Ironwood Pharmaceuticals. The companies reached an agreement Tuesday to resolve litigation surrounding Sun’s submission of an abbreviated new drug application for a generic of Linzess (linaclotide capsules).
As part of the agreement, Allergan and Ironwood have granted Sun Pharma and its subsidiaries a license to market its generic of the treatment for irritable bowel syndrome treatment with constipation and chronic idiopathic constipation in the United States starting Feb. 1, 2031 or earlier under certain circumstances. The launch would be subject to Food and Drug Administration approval.
“Ironwood and Allergan have established Linzess as the branded prescription market leader in the IBS-C and CIC category,” Ironwood chief commercial officer Tom McCourt said. “We are pleased to have resolved this patent litigation with Sun Pharma, as we believe it confirms the strength of our Linzess intellectual property. Allergan and Ironwood are committed to continuing to grow the Linzessfranchise for many years to come.”
January 16, 2018